DeepSight Technology, a leader in medical imaging innovation, has received U.S. FDA 510(k) clearance for its NeedleVue™ LC1 Ultrasound System. This milestone advances the company’s NeedleVue™ and OnPoint™ technologies, designed to revolutionize image-guided procedures.
“Our mission is to deliver crystal-clear, sub-millimeter precision inside the body,” said Nader Sadrzadeh, CEO of DeepSight. “Our next-generation sensor technology enhances ultrasound where it matters most—improving visualization, procedural efficiency, and clinician confidence. This clearance marks just the beginning as we scale our clinical and commercial momentum.”
Healthcare professionals can explore the NeedleVue™ LC1 firsthand at LSI’25 Europe in London (September 7–11) and at the CIRSE conference in Barcelona (September 13–17).